{{Rsnum
|rsid=3769376
|Gene=CYTIP
|Chromosome=2
|position=157421733
|Orientation=plus
|GMAF=0.04959
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
|Gene_s=CYTIP
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 0.0 | 1.8 | 98.2
| HCB | 1.5 | 15.3 | 83.2
| JPT | 0.9 | 14.2 | 85.0
| YRI | 0.7 | 12.2 | 87.1
| ASW | 0.0 | 8.8 | 91.2
| CHB | 1.5 | 15.3 | 83.2
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 9.9 | 90.1
| LWK | 0.0 | 5.5 | 94.5
| MEX | 0.0 | 17.2 | 82.8
| MKK | 0.0 | 9.6 | 90.4
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs3769376
|Name_s=
|Gene_s=CYTIP
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: C, MAF= 0.03, combined P value= 1.51E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470200
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs3769376
|overall_frequency_n=7
|overall_frequency_d=128
|overall_frequency=0.0546875
|n_genomes=8
|n_genomes_annotated=0
|n_haplomes=8
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=2
|webscore=N
|n_web_uneval=5
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}